The Role of Rituximab in Allogeneic Hematopoietic Cell Transplantation for B-Cell Non-Hodgkin Lymphoma
Non-Hodgkin lymphoma (NHL) is an increasingly common cancer. For many patients, the only potentially curative treatment is blood stem cell transplantation. However, such transplants can fail either because of lymphoma recurrence or because of complications such as graft-vs.-host disease. Dr. Rezvani’s research focuses on using rituximab, a monoclonal antibody, to try to reduce these risks. He and his lab are also performing laboratory investigations to determine the optimal dose of rituximab and to identify the patients most likely to benefit. Ultimately, Dr. Rezvani’s goal is to find safer and more effective ways of performing blood stem cell transplants for people with NHL.